Featured Research Search Results
Comparing Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (Rasolute 303)
Clinicaltrials.gov identifier:
NCT07491445
Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
Clinicaltrials.gov identifier:
NCT06974110
Treatment
Treatment study for people with advanced or metastatic cancers
Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study
Clinicaltrials.gov identifier:
NCT06995898
Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
Clinicaltrials.gov identifier:
NCT07252232
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
Clinicaltrials.gov identifier:
NCT06782932
Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Vaccine for People at High Risk for Pancreatic Cancer
Clinicaltrials.gov identifier:
NCT05013216
Prevention
Phase 1 pancreatic cancer prevention study for people at high risk
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
Clinicaltrials.gov identifier:
NCT05059444
Treatment
Post-treatment study to monitor for recurrence
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
Clinicaltrials.gov identifier:
NCT05463796
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
The EASE Study: Helping People with Advanced Cancer Cope with Fear of Cancer Progression
Clinicaltrials.gov identifier:
NCT07636200
Quality of Life
Quality of life study for people with advanced cancer experiencing anxiety
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
Clinicaltrials.gov identifier:
NCT06128551
Treatment
Phase 1/2 treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors
Clinicaltrials.gov identifier:
NCT06411691
Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation
Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
Clinicaltrials.gov identifier:
NCT05372640
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
Clinicaltrials.gov identifier:
NCT06177171
Treatment
Phase 1 treatment study for metastatic solid tumors
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Clinicaltrials.gov identifier:
NCT06958328
Treatment
Radiation treatment study for people with locally advanced pancreatic cancer
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Screening Study for Pancreatic Cancer in People with Inherited Mutations
Clinicaltrials.gov identifier:
NCT05058846
Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations
Sponsored By
